245 related articles for article (PubMed ID: 35684445)
1. Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.
Petrenko D; Chubarev V; Syzrantsev N; Ismail N; Merkulov V; Sologova S; Grigorevskikh E; Smolyarchuk E; Alyautdin R
Molecules; 2022 May; 27(11):. PubMed ID: 35684445
[TBL] [Abstract][Full Text] [Related]
2. Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy.
Du K; Xia Q; Sun J; Feng F
ACS Appl Mater Interfaces; 2021 Dec; 13(47):55851-55861. PubMed ID: 34788006
[TBL] [Abstract][Full Text] [Related]
3. Progress in research and development of temozolomide brain-targeted preparations: a review.
Yang J; Xu Y; Fu Z; Chen J; Fan W; Wu X
J Drug Target; 2023 Feb; 31(2):119-133. PubMed ID: 36039767
[TBL] [Abstract][Full Text] [Related]
4. Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment.
Iturrioz-RodrÃguez N; Sampron N; Matheu A
Theranostics; 2023; 13(9):2734-2756. PubMed ID: 37284445
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme.
Li X; Shao F; Sun J; Du K; Sun Y; Feng F
ACS Appl Mater Interfaces; 2019 Nov; 11(45):41935-41945. PubMed ID: 31644262
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.
Bikhezar F; de Kruijff RM; van der Meer AJGM; Torrelo Villa G; van der Pol SMA; Becerril Aragon G; Gasol Garcia A; Narayan RS; de Vries HE; Slotman BJ; Denkova AG; Sminia P
J Neurooncol; 2020 Jan; 146(2):239-246. PubMed ID: 31875307
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
[TBL] [Abstract][Full Text] [Related]
8. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
He Y; Kaina B
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
[TBL] [Abstract][Full Text] [Related]
9. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
[TBL] [Abstract][Full Text] [Related]
10. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
11. Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.
Yamamoto Y; Sasaki N; Kumagai K; Takeuchi S; Toyooka T; Otani N; Wada K; Narita Y; Ichimura K; Namba H; Mori K; Tomiyama A
Neurol Med Chir (Tokyo); 2018 Jul; 58(7):296-302. PubMed ID: 29899179
[TBL] [Abstract][Full Text] [Related]
12. Polymer-Drug Conjugates Codeliver a Temozolomide Intermediate and Nitric Oxide for Enhanced Chemotherapy against Glioblastoma Multiforme.
Du K; Li X; Feng F
ACS Appl Bio Mater; 2024 Mar; 7(3):1810-1819. PubMed ID: 38403964
[TBL] [Abstract][Full Text] [Related]
13. Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide.
Ding Y; Zhang C; He L; Song X; Zheng C; Pan Y; Yu S
Bioengineered; 2021 Dec; 12(2):10791-10798. PubMed ID: 34753395
[TBL] [Abstract][Full Text] [Related]
14. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
15. PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma.
Li PC; Chen SY; Xiangfei D; Mao C; Wu CH; Shih JC
BMC Complement Med Ther; 2020 Aug; 20(1):252. PubMed ID: 32799864
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis.
Karami A; Hossienpour M; Mohammadi Noori E; Rahpyma M; Najafi K; Kiani A
Nutr Cancer; 2022; 74(4):1299-1307. PubMed ID: 34296963
[TBL] [Abstract][Full Text] [Related]
17. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia.
Dang W; Xiao J; Ma Q; Miao J; Cao M; Chen L; Shi Y; Yao X; Yu S; Liu X; Cui Y; Zhang X; Bian X
Brain Tumor Pathol; 2021 Jul; 38(3):189-200. PubMed ID: 34231121
[TBL] [Abstract][Full Text] [Related]
18. CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.
Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Lenz GS; de Oliveira FH; Wink MR; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1177-1182. PubMed ID: 32417936
[TBL] [Abstract][Full Text] [Related]
19. Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma.
Janjua TI; Cao Y; Ahmed-Cox A; Raza A; Moniruzzaman M; Akhter DT; Fletcher NL; Kavallaris M; Thurecht KJ; Popat A
J Control Release; 2023 May; 357():161-174. PubMed ID: 36965857
[TBL] [Abstract][Full Text] [Related]
20. Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH
Wan Z; Li C; Gu J; Qian J; Zhu J; Wang J; Li Y; Jiang J; Chen H; Luo C
Int J Nanomedicine; 2021; 16():6905-6922. PubMed ID: 34675514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]